Literature DB >> 16223509

Minimum prevalence of spinocerebellar ataxia 17 in the north east of England.

Kate Craig1, Sharon M Keers, Timothy J Walls, Anne Curtis, Patrick F Chinnery.   

Abstract

OBJECTIVE: To determine the minimum prevalence of spinocerebellar ataxia type 17 (SCA17) in the north east of England. PATIENTS AND METHODS: A defined region containing 2,516,500 individuals with 192 families with undiagnosed ataxia, 90 patients with a Huntington's disease-like phenotype and 292 controls. The number of (CAG/CAA)(n) repeats in the SCA17/TBP gene was determined by fluorescent PCR and sequenced in affected individuals.
RESULTS: The mean repeat size for 584 control alleles was 34 (S.D.=3.58), ranging from 25 to 40. Two index cases had larger alleles with repeat lengths greater than the control range. Affected family members presented in adult life with ataxia followed by extrapyramidal features and cognitive impairment. In one family 44 repeats were associated with a younger age of onset than has been previously described.
CONCLUSIONS: The minimum prevalence of SCA17 in the north east of England was 0.16/100,000 (upper 95% confidence interval 0.31/100,000).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223509     DOI: 10.1016/j.jns.2005.08.009

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  CAG repeats determine brain atrophy in spinocerebellar ataxia 17: a VBM study.

Authors:  Kathrin Reetz; Alexandra Kleiman; Christine Klein; Rebekka Lencer; Christine Zuehlke; Kathrin Brockmann; Arndt Rolfs; Ferdinand Binkofski
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

Review 2.  A systematic review of the incidence and prevalence of long-term neurological conditions in the UK.

Authors:  Thomas Hoppitt; Hardev Pall; Mel Calvert; Paramjit Gill; Guiqing Yao; Jill Ramsay; Gill James; Jacky Conduit; Cath Sackley
Journal:  Neuroepidemiology       Date:  2010-11-17       Impact factor: 3.282

3.  Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis.

Authors:  Su Yang; Xiao-Jiang Li; Shihua Li
Journal:  Rare Dis       Date:  2016-08-12

Review 4.  Spinocerebellar ataxia type 17 is caused by mutations in the TATA-box binding protein.

Authors:  Christine Zühlke; Katrin Bürk
Journal:  Cerebellum       Date:  2007-01-19       Impact factor: 3.847

5.  Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).

Authors:  Giovanni Stevanin; Alexis Brice
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

6.  Spinocerebellar ataxia type 17 (SCA17): oculomotor phenotype and clinical characterization of 15 Italian patients.

Authors:  Caterina Mariotti; Dario Alpini; Roberto Fancellu; Paola Soliveri; Marina Grisoli; Sabrina Ravaglia; Carlo Lovati; Vincenza Fetoni; Giorgio Giaccone; Alessia Castucci; Franco Taroni; Cinzia Gellera; Stefano Di Donato
Journal:  J Neurol       Date:  2007-10-15       Impact factor: 4.849

Review 7.  Huntington's Disease, Huntington's Disease Look-Alikes‎, and Benign Hereditary Chorea: What's New?

Authors:  Susanne A Schneider; Thomas Bird
Journal:  Mov Disord Clin Pract       Date:  2016-01-27

8.  From mild ataxia to huntington disease phenocopy: the multiple faces of spinocerebellar ataxia 17.

Authors:  Georgios Koutsis; Marios Panas; George P Paraskevas; Anastasia M Bougea; Athina Kladi; Georgia Karadima; Elisabeth Kapaki
Journal:  Case Rep Neurol Med       Date:  2014-10-02

Review 9.  Prevalence of neurogenetic disorders in the North of England.

Authors:  David Bargiela; Patrick Yu-Wai-Man; Michael Keogh; Rita Horvath; Patrick F Chinnery
Journal:  Neurology       Date:  2015-09-04       Impact factor: 9.910

10.  Complexity of the Genetics and Clinical Presentation of Spinocerebellar Ataxia 17.

Authors:  Suran Nethisinghe; Wei N Lim; Heather Ging; Anna Zeitlberger; Rosella Abeti; Sally Pemble; Mary G Sweeney; Robyn Labrum; Charisse Cervera; Henry Houlden; Elisabeth Rosser; Patricia Limousin; Angus Kennedy; Michael P Lunn; Kailash P Bhatia; Nicholas W Wood; John Hardy; James M Polke; Liana Veneziano; Alfredo Brusco; Mary B Davis; Paola Giunti
Journal:  Front Cell Neurosci       Date:  2018-11-23       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.